---
id: ash-anticoagulation-cancer-2024
title: "ASH 2024 Guidelines on Anticoagulation for VTE in Patients with Cancer"
short_title: "ASH Cancer VTE 2024"

organization: American Society of Hematology
collaborators: null
country: US
url: https://www.hematology.org/guidelines
doi: null
pmid: null
open_access: true

specialty: hematology
guideline_type: clinical-practice
evidence_system: ASH GRADE
conditions:
  - cancer-associated thrombosis
  - VTE in cancer
  - pulmonary embolism
  - deep vein thrombosis
tags:
  - DOACs
  - LMWH
  - anticoagulation duration
  - bleeding risk
  - GI cancer

publication_date: 2024-06-01
previous_version_date: 2021-11-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 ASH guideline update on the treatment and prophylaxis of venous thromboembolism (VTE) in patients with cancer.

## Key Recommendations

### Treatment of Cancer-Associated VTE

#### Initial Therapy
- **DOACs (Preferred for Most Patients)**: Apixaban, edoxaban, rivaroxaban.
  - Superior to or non-inferior to LMWH for recurrence; easier administration.
- **LMWH**: Preferred for high GI bleeding risk (luminal GI/GU malignancies) or significant drug interactions.
- **Warfarin**: Generally NOT recommended due to inferior efficacy and drug interactions.

#### Duration
- **At Least 6 Months**: For all cancer-associated VTE.
- **Extended Anticoagulation**: Continue beyond 6 months while cancer is active or on cancer treatment; reassess periodically.

### Prophylaxis in Ambulatory Cancer Patients
- Routine prophylaxis NOT recommended for all ambulatory patients on chemotherapy.
- **High-Risk Patients (Khorana Score â‰¥2 + Additional Risk Factors)**: Consider thromboprophylaxis with DOAC (apixaban 2.5 mg BID, rivaroxaban 10 mg daily) if bleeding risk is low.

### Surgical Cancer Patients
- Pharmacologic prophylaxis (LMWH or UFH) pre- and post-operatively.
- Extended prophylaxis (4 weeks) for major abdominal/pelvic cancer surgery.

### Hospitalized Medical Cancer Patients
- Pharmacologic prophylaxis during hospitalization.
- Extended post-discharge prophylaxis: Consider for high-risk patients.

### Incidental VTE
- Treat the same as symptomatic VTE if clinically significant (segmental or larger PE, proximal DVT).
- Subsegmental PE and distal DVT: Individualize based on bleeding risk and tumor burden.

### Recurrent VTE on Anticoagulation
- Ensure adherence; consider switching anticoagulant class or increasing dose.
